Clinical effects of the addition of cannabidiol to the usual treatment of patients with diagnosis of Obsessive Compulsive Disorder

Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo0 个研究点开始时间: 2023年3月29日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients of both sexes; aged between 18 and 65 years; diagnosed with obsessive-compulsive disorder; undergoing outpatient pharmacological treatment with selective serotonin reuptake inhibitors or clomipramine; with current symptoms of obsessions, compulsions or both; with severity assessed by the scale Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) (score greater than or equal to 20 out of a total of 40 possible points).

•Age under 18 and over 65 years; presence of relevant medical condition (cardiovascular diseases, severe arterial hypertension, renal failure, liver disease, hypothyroidism, hyponatremia, hypovitaminosis B12, previous intracranial hypertension, epilepsy, pregnancy, breastfeeding); history of neurological disease (including severe traumatic brain injury and excluding headache); previous use of cannabis in the last month or history of dependence on any other psychoactive substance; previous history of allergy or idiosyncratic reactions to cannabis sativa derivatives; psychotic symptoms; suicidal ideation; personality disorder or diagnosis of substance use disorder according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Patients with changes in their pharmacological regimen in the last 30 days will not be able to participate in the study. Patients using medications that modulate the glutamatergic system (topiramate, lamotrigine, memantine) and benzodiazepines will be excluded

发起方

Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo